

EXPERIENCE

Novartis Pharmaceutical Corporation, East Hanover, NJ (2015 - Present)

- Senior Global Program Clinical Head, Communicable Diseases, Global Health Development

Novartis Vaccines and Diagnostics, Cambridge, MA (2013 – 2014)

- Development Cluster Head, Cell Culture Based Influenza Vaccines

Pfizer Inc. Emerging Markets Business Unit, NY, NY (2009 – 2013)

- Global Program Team Head, Malaria & Vaccines (2012 – 2013)
- Global Program Team Head, Malaria (2009 – 2012)

Pfizer Global Research & Development, Groton/New London, CT (1999 –2009)

- Global Clinical Lead, Malaria (2007-2009)
- Global Translational Medicine Head, Infectious Diseases (2003 – 2007)
- Early Clinical Portfolio Leader, Antibacterial Agents (1999 – 2003)

Pfizer (India) Limited, Mumbai (1994 – 1999)

- VP and Head, International Clinical Research & Biometrics (1997 – 1999)
- Manager, Scientific & Public Affairs (1995 – 1997)
- Medical Advisor, Infectious Diseases, Inflammation, Cardiovascular Diseases (1994 – 1995)

Roussel Uclaf (India) Ltd (1993 – 1994)

- Medical Advisor, Infectious Diseases, Inflammation

Seth GS Medical College & KEM Hospital, Mumbai, India (1987 – 1992)

- Lecturer, Clinical Pharmacology & Therapeutics

KEY CONTRIBUTIONS

Infectious Diseases Development at Novartis (2013 - Present)

Neglected Tropical Disease (NTD) Programs

- Lead development of clinical development strategies for internal NTD portfolio including Fascioliasis (post approval commitments) and research/early development programs in collaboration with internal and external stakeholders
- Internal consultant to Malaria Global Program Team
- At quarterly NTD Decision Board meetings, review NTD research portfolio, advise teams and participate in decision making from development perspective

Antibacterial Programs

- As the Senior Global Program Clinical Head on clofazimine program contribute to development and access strategies for MDR-TB and Leprosy indications, and Managed Access Program for NTM
- Led the Global Clinical Team (GCT) for tobramycin inhalational products to develop and implement clinical development strategies for Cystic Fibrosis (CF) and Bronchiectasis (BE) indications in collaboration with CF foundation, IMI and other external collaborators
- Led a cross-functional team to develop innovative clinical/registration strategies for early clinical development programs for serious infections with high unmet need
- Worked closely with portfolio decision analytics and external collaborators to develop and pilot a new decision analytics tool for portfolio strategy and prioritization
- Led clinical review of external opportunities

RICHA CHANDRA, MD, MBBS, MBA

Antiviral Programs

- Led telbivudine Hepatitis B clinical development program in adults and children (2015)
- Led development of clinical development strategies for research /early development portfolio (2015)

Vaccines

- Led development and implementation of clinical and regulatory strategies for cell based influenza vaccine programs in adults, elderly and children (2013-2014)

Other contributions

- As a member of the internal Scientific Review Committee, advise teams on clinical development plans and study protocols for Global Health development portfolio at monthly meetings
- At monthly Infectious Diseases Decision Board meetings, reviewed projects, advised research teams and participated in decision making from development perspective (2015-2018)
- Led development of internal guidance documents on inclusion/exclusion and monitoring of patients with hepatitis and tuberculosis in protocols being developed for indications other than hepatitis or tuberculosis

Infectious Disease Development at Pfizer (2007-2013)

Malaria Program

- Led the Global Program Team to develop an innovative and implementable development and access strategy for intermittent preventive treatment of malaria in pregnancy (IPTp) in collaboration with external stakeholders including Medicines for Malaria Venture (MMV), London School of Hygiene and Tropical Medicine, WHO, African governments (regulatory agencies, National Malaria Control and Maternal & Child Health Programs) and global funding agencies. The Team was recognized as the Finalist for GBC (Global Business Council for HIV, Malaria and TB) Award in 2011.
- Led Phase 2/ 3 development of azithromycin/chloroquine for IPTp indication in pregnant women in sub-Saharan Africa, and for treatment of acute uncomplicated malaria in sub-Saharan Africa and Asia
- Served as a core member on **WHO's** Malaria in Pregnancy Working Group
- Participated as a core member on **Gates Foundation** sponsored **MalERA** Drug Development Working Group to develop Malaria TPPs and setting research priorities
- Collaborated with Biko Center of Bioethics (Johannesburg) for conducting regional workshops on conducting research in vulnerable populations
- Collaborated with WHO/TDR on Gates Foundation funded Global Health Fellow program for capacity building in developing nations
- Represented pharma industry at a WHO workshop on setting research priorities for developing nations
- Invited as a guest speaker / expert on conducting clinical trials in developing nations

Vaccines

- Partnered with Global Program Teams to develop clinical and registration strategy for antibacterial vaccines in research/ early development with focus on developing countries (2012-2013)

Translational Medicine and Exploratory Development (1999-2007)

- Led translational medicine and early development strategy, planning and execution of the antibacterial and antiviral programs up to clinical Proof of Concept
- As a member of the Technical Advisory Committees in Research and in Infectious Disease Development, guided project teams in project prioritization, strategy, planning, and decision making
- Led clinical pharmacology program for Zmax through regulatory submission and approval

International Clinical Research, Biometrics and IT Operations, Pfizer India (1997-1999)

- Established a department of 58 colleagues to participate in global registration trials
- Led the India team to participate in global clinical trials across therapeutic areas/indications: *infectious diseases* (CAP, sinusitis, otitis media, typhoid fever, invasive aspergillosis, candidemia, malaria), *Oncology* (advanced breast cancer) and *Neuroscience* (resistant schizophrenia and manic depressive psychosis)
- Collaborated with Ministry of Health (MoH), Drugs Controller General of India (DCGI's office), Indian Council of Medical Research (ICMR) and academia to develop national GCP and Research Ethics Guidelines and establish the first independent Ethics Committee in India

RICHA CHANDRA, MD, MBBS, MBA

- In collaboration with Pfizer global R&D and Indian Ministry of Science and Technology led the conduct of five regional workshops on IPR and pharmaceutical product patents for hundred national research laboratories under Council for Scientific and Industrial Research (CSIR)

Scientific and Public Affairs, Pfizer India (1995-1997)

- Corporate spokesperson on R&D and policy issues
- In collaboration with Federation of Indian Chambers of Commerce and Industries (FICCI), led a large nationwide quantitative/qualitative research on public perception about implementation of pharmaceutical product patents in India
- As part of a 5-member PhRMA delegation, participated in the presentation / discussion on the industry perspective on the new patent bill tabled in the Upper House of Parliament (Rajya Sabha)

Medical Advisor, Pfizer India (1994 – 1995)

- Provided medical support for anti-infective/ anti-inflammatory portfolio, and led/ co-led medical aspects of pre-launch, launch, post launch activities for azithromycin and prazosin GITS

Medical Advisor, Pfizer India and Roussel Uclaf (1993 - 1994)

- Provided medical support for anti-infective/ anti-inflammatory portfolio, and led medical aspects of pre-launch, launch, post launch activities for cefotaxime and roxithromycin

Lecturer, Clinical Pharmacology and Therapeutics, Seth GS Medical College, Mumbai (1987-1992)

- Taught medical (MBBS, MD), nursing, occupational and physical therapy students through lectures, tutorials and bedside clinics

EDUCATION

M.B.A.	Rensselaer Polytechnic Institute (RPI) Independent Study: Probabilistic portfolio decision analysis model for multiple-candidate strategy in anti-infective drug development	2001-2004
D.N.B. (Clin. Pharm)	Seth GS Medical College & KEM Hospital, Mumbai	1990-1992
M.D.	Pharmacology & Therapeutics Seth GS Medical College & KEM Hospital, Mumbai	1986-1989
M.B.B.S.	Bachelor of Medicine & Bachelor of Surgery Lady Hardinge Medical College, New Delhi	1980-85

LANGUAGES **English, Hindi**

PUBLICATIONS **Upon Request**